CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients

Cisplatin-based chemotherapy is the foundation of treatment for major non-small cell lung cancer (NSCLC) patients. However, cisplatin resistance is still a challenging issue, and the molecular mechanisms underlying this resistance remain to be fully explored. CLEC4M, a Ca(2+)-dependent C-type lectin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Li-Ming, Li, Xi, Qiu, Cheng-Feng, Zhu, Tao, Hu, Cheng-Ping, Yin, Ji-Ye, Zhang, Wei, Zhou, Hong-Hao, Liu, Zhao-Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856750/
https://www.ncbi.nlm.nih.gov/pubmed/31772670
http://dx.doi.org/10.7150/jca.30139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856750/
https://www.ncbi.nlm.nih.gov/pubmed/31772670
http://dx.doi.org/10.7150/jca.30139

Ejemplares similares